eLaws | eCases | United States Code | Federal Courts |

AARP - Comment

Document ID: FDA-2011-N-0326-0034
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: January 06 2012, at 12:00 AM Eastern Standard Time
Date Posted: January 11 2012, at 12:00 AM Eastern Standard Time
Comment Start Date: December 7 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: January 6 2012, at 11:59 PM Eastern Standard Time
Tracking Number: 80f8ecda
View Document:

This is comment on Notice

Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting

View Comment

See attached file(s)

Attachments:

AARP comments on Biosimilar User Fees Final

Title:
AARP comments on Biosimilar User Fees Final

View Attachment:

View as format pdf

Related Comments

View All

Total: 12

Academy of Managed Care Pharmacy (AMCP) - Comment
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0026

Comment Period Closed
Jan 06,2012 11:59 PM ET

Shein-Chung Chow, PhD Duke University School of Medicine - Testimony
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0027

Comment Period Closed
Jan 06,2012 11:59 PM ET

BIO - Testimony
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0028

Comment Period Closed
Jan 06,2012 11:59 PM ET

Pfizer Inc - Comment
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0032

Comment Period Closed
Jan 06,2012 11:59 PM ET

AARP - Comment
Public Submission Posted: 01/11/2012 ID: FDA-2011-N-0326-0034

Comment Period Closed
Jan 06,2012 11:59 PM ET